Considering that intracellular signaling pathways that modulate brain BDNF are implicated in antidepressant responses, this study investigated whether signaling pathway inhibitors upstream to BDNF might influence the antidepressant-like effect of zinc, a metal that has been shown to display antidepressant properties. To this end, the influence of i.c.v. administration of H-89 (1 μg/site, PKA inhibitor), (1 μg/site, CAMKII inhibitor), chelerythrine (1 μg/site, PKC inhibitor), PD98059 (5 μg/site, MEK1/2 inhibitor), U0126 (5 μg/site, MEK1/2 inhibitor), LY294002 (10 nmol/site, PI3K inhibitor) on the reduction of immobility time in the tail suspension test (TST) elicited by ZnCl 2 (10 mg/kg, p.o.) was investigated. Moreover, the effect of the combination of subeffective doses of ZnCl 2 (1 mg/kg, p.o.) and AR-A014418 (0.001 μg/site, GSK-3β inhibitor) was evaluated. The occurrence of changes in CREB phosphorylation and BDNF immunocontent in the hippocampus and prefrontal cortex of mice following ZnCl 2 treatment was also investigated. The anti-immobility effect of ZnCl 2 in the TST was prevented by treatment with PKA, PKC, CAMKII, MEK1/2 or PI3K inhibitors. Furthermore, ZnCl 2 in combination with AR-A014418 caused a synergistic anti-immobility effect in the TST. None of the treatments altered locomotor activity of mice. ZnCl 2 treatment caused no alteration in CREB phosphorylation and BDNF immunocontent. The results extend literature data regarding the mechanisms underlying the antidepressantlike action of zinc by indicating that its antidepressant-like effect may be dependent on the activation of PKA, CAMKII, PKC, ERK, and PI3K/GSK-3β pathways. However, zinc is not able to acutely increase BDNF in the hippocampus and prefrontal cortex.
Introduction
Depression is a common, chronic and disabling psychiatric disorder, resulting in a social and economic burden, besides enormous personal suffering and increased mortality risk (Lepine and Briley, 2011) . Although there are several classes of antidepressants, the use of these drugs is associated with several side effects (Bet et al., 2013) , a delay in symptom remission (Nemeroff and Owens, 2002) and a large number of partial responses or lack of responses (Ruhe et al., 2011) . These factors underscore the need to investigate alternative treatments or prevention strategies for depression.
Zinc is one of the agents used in the augmentation therapies for the treatment of depression (Lai et al., 2012; Swardfager et al., 2013; Szewczyk et al., 2008) and the concentration of this element in the blood can be used as a marker of depression (Siwek et al., 2013) . Serum zinc levels are reported to be decreased in depressed patients (Maes et al., 1999 , Maes et al.,1997 Siwek et al., 2010) and increased after the treatment with antidepressants (Siwek et al., 2010) . Notably, serum zinc levels were correlated with the severity of depression (Irmisch et al., 2010) and zinc supplementation improved the efficacy of antidepressants in patients that were resistant to drug therapy (Siwek et al., 2009) . Recently, zinc monotherapy was reported to improve mood in overweight or obese subjects most likely by increasing BDNF levels (Solati et al., 2014) . Consistent with these data, it is well established that zinc supplementation provides an antidepressant-like effect in predictive tests for antidepressant activity (Brocardo et al., 2007; Cunha et al., 2008; Franco et al., 2008; Kroczka et al., 2001; Lobato et al., 2008; Nowak et al., 2003; Rosa et al., 2003; Sowa-Kucma et al., 2008; Szewczyk et al., 2009 ) and zinc-deficient diet leads to a depressive-like effect Mlyniec and Nowak, 2012; Tamano et al., 2009; Tassabehji et al., 2008; Whittle et al., 2009) .
Zinc has been reported to activate metabotropic GPR39 (Besser et al., 2009; Yasuda et al., 2007) , a G protein-coupled receptor 39 that is widely expressed in the central nervous system (Howard et al., 2001) . Of note, zinc-deficient diet for six weeks is associated with a significant reduction in GPR39 receptor and brain-derived neurotrophic factor (BDNF) protein expression in the frontal cortex of mice as well as a depressive-like behavior . Zinc-deficient diet for six weeks also decreased expression of CREB and BDNF in the hippocampus (Mlyniec et al., 2014) . GPR39 expression was decreased in the hippocampus and frontal cortex of zinc deficient mice and rats as well as in the hippocampus and cerebral cortex of suicide victims (Mlyniec et al., 2014) . Zinc deficient diet for four or six weeks also decreased p-CREB and BDNF levels in the hippocampus (Doboszewska et al., 2015) . On the other hand, chronic treatment with zinc induced an increase in cortical BDNF mRNA level (Nowak et al., 2004) .
Despite the devastating impact of depression, its pathophysiology and etiology are not completely clarified. The monoaminergic neurotransmitter system has received great attention in depression, and its importance is confirmed by the fact that effective antidepressant drugs exert their primary biochemical effects by regulating monoaminergic neurotransmission (Nemeroff and Owens, 2002) . Although most antidepressants increase the levels of monoamines acutely, clinical response in humans occurs only after chronic treatment, suggesting that the activation of cellular signaling pathways associated with neuroplasticity and cellular survival are required for the effectiveness of antidepressants. Consistent with this assumption, several preclinical and clinical studies have shown that intracellular signaling pathways are targets for the actions of antidepressant agents (Kitagishi et al., 2012; Marsden, 2013) .
BDNF is a neurotrophin downstream to several cellular signaling pathways widely recognized as a key target implicated both in the etiology of depression and in the antidepressant drug action (Castren and Rantamaki, 2010; Duman and Monteggia, 2006) . According to a meta-analysis, depressive patients have a decrease in serum and plasma BDNF levels (Bocchio-Chiavetto et al., 2010) . On the other hand, peripheral BDNF administration produces an antidepressant-like behavior in mice (Schmidt and Duman, 2010) . Likewise, a metaanalysis showed that antidepressant treatment increased serum and plasma BDNF levels in depressive patients (Brunoni et al., 2008) . Regarding brain BDNF levels following antidepressant treatments in rodents, it is widely reported that chronic, but not acute administration of these agents is associated with enhanced BDNF levels in the hippocampus and prefrontal cortex (Balu et al., 2008; De Foubert et al., 2004) . Of note, the NMDA receptor antagonist ketamine administered acutely has been shown to increase BDNF levels in the hippocampus and prefrontal cortex of rats and mice (Garcia et al., 2008; Zhou et al., 2014) . However, it remains to be established if zinc, that is also an NMDA receptor antagonist, is able to acutely produce such effect.
Many intracellular signal transduction cascades can influence, directly or indirectly, the activation of cAMP response element binding protein (CREB), which in turn is responsible for the expression of BDNF. Some of the enzymes that participate in these cascades are protein kinase A (PKA), protein kinase C (PKC), Ca 2+ /calmodulindependent protein kinase (CAMKII), extracellular-regulated protein kinase (ERK), phosphoinositide 3-kinase (PI3K), and glycogen synthase kinase 3 (GSK-3) (Hashimoto et al., 2004; Malberg and Blendy, 2005) . Taking into account the importance of BDNF for depression and that several studies have suggested that the antidepressant-like effect of zinc may involve BDNF increase, this study aimed at investigating whether selective inhibitors of signaling enzymes (upstream to BDNF) might influence the antidepressant-like effect of zinc and if, similarly to the result reported for ketamine, the acute administration of zinc is able to increase brain BDNF levels.
Materials and methods

Animals
Female Swiss mice (45-55 days old, weighing 30-45 g) were maintained at 20-22°C with free access to water and food, under a 12:12 h light:dark cycle (lights on at 7:00 a.m.). The animals were caged in groups of 15 in a 41 × 34 × 16-cm cage. All behavioral tests were carried out between 9:00 a.m. and 04:00 p.m. Animals were acclimatized to the laboratory for at least 12 h before testing. The animals were used according to the NIH Guide for the Care and Use of Laboratory Animals and the experiments were performed after approval of the protocol by the Ethics Committee of the Institution. All efforts were made to minimize animal suffering and to reduce the number of animals used in the experiments.
Drugs and treatment
The following drugs were used: zinc chloride (ZnCl 2 ) (1 or 10 mg/kg),
(1 μg/site, CAMKII inhibitor), chelerythrine (1 μg/site, PKC inhibitor), PD98059 (5 μg/site, inhibitor of mitogen-activated protein kinase kinase (MAPKK/MEK 1/2)), U0126 (5 μg/site, inhibitor of MEK1/2), LY294002 (10 nmol/site, PI3K inhibitor), AR-A014418 (0.001 μg/site, selective GSK-3β inhibitor). All these drugs were obtained from SigmaAldrich Chemical Co., St. Louis, USA. ZnCl 2 was dissolved in distilled water and administered orally (p.o.). H-89, KN-62, chelerythrine, PD98059, U0126, LY294002, AR-A014418 were dissolved in saline (0.9% NaCl) at a final concentration of 1% dimethyl sulfoxide (DMSO) and administered by intracerebroventricular (i.c.v.) route. The drugs were freshly prepared before treatment and administered in a volume of 10 ml/kg body weight (p.o. route) or 5 μl/site (i.c.v. route). Control animals received the appropriate vehicle.
I.c.v. administration was performed as described previously (Kaster et al., 2012) . For injection, 26 G needle was attached to a polypropylene cannula coupled to a Hamilton microsyringe 50 μl. The mice were lightly anesthetized with isoflurane (2.5%; Abbot Laboratórios do Brasil Ltda., Rio de Janeiro, RJ, Brazil) using a vaporizer system (SurgiVet Inc., Waukesha, WI, USA). The administration was performed by inserting the needle perpendicularly through the skull and no more than 2 mm into the brain of the mice. The injection was given over 30 s, and the needle remained in place for another 30 s in order to avoid the reflux of the substances injected. The injection site was 1 mm to the right or left from the midpoint on a line drawn through to the anterior base of the ears. The injections were performed by an experienced person, and after dissection of the brain of the animal, the success of the injection was examined, macroscopically, discarding animals whose injection has been held in inappropriate place or has caused cerebral hemorrhage (b 5%).
To test the hypothesis that the antidepressant-like effect of zinc is dependent on the activation of intracellular signaling pathways, mice were pretreated with an effective dose of ZnCl 2 (10 mg/kg, p.o.), and 30 min later they received sub-effective doses of either H-89, KN-62, PD98059, U0126, chelerythrine or LY294002. The animals were submitted to behavioral tests 30 min later (60 min after zinc administration). Moreover, to investigate a possible synergistic effect between zinc and GSK-3β inhibitor, animals received (p.o.) vehicle or a sub-effective dose of ZnCl 2 (1 mg/kg). After 30 min, they received (i.c.v.) a subeffective dose of AR-A014418 or vehicle. Thirty minutes after the end of the last treatment, the behavioral tests were performed.
The doses of ZnCl 2 used were chosen based on experiment previously performed in our laboratory (Cunha et al., 2008) . The doses of H-89, KN-62, chelerythrine, PD98059, U0126, LY294002, and AR-A014418 were chosen based on experiments previously performed in our laboratory or other groups (Almeida et al., 2006; Budni et al., 2011; Cunha et al., 2014; Moretti et al., 2014; Zeni et al., 2012) . The number of animals used for behavioral tests was 7-8 per group.
Behavioral tests 2.3.1. Tail suspension test (TST)
The total duration of immobility induced by tail suspension was measured according to the method described by Steru et al. (1985) . Mice both acoustically and visually isolated were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Mice were considered immobile only when they hung passively and completely motionless. The immobility time was recorded during a 6-min period by an experienced observer. A decreased immobility time was considered indicative of an antidepressant-like effect (Steru et al., 1985) .
Open-field test
In order to exclude the possibility that the alteration in the immobility time in the TST is due to interference of locomotor activity, the animals were subjected to an open-field test for 6 min, as described by Moretti et al. (2014) . This test was conducted in a wooden box measuring 40 × 60 × 50 cm, with the floor of the arena divided into 12 equal squares. At the start of each trial a mouse was placed in the left corner of the field and was allowed to freely explore the arena. The number of squares crossed with all four paws (crossings) was manually counted and was the parameter used to indicate locomotor activity. The apparatus was cleaned with a solution of 10% ethanol between tests in order to hide animal clues. The test was carried out in a temperature and light controlled room.
Biochemical analysis
Independent groups of mice (n = 4-8 per group) were used to biochemical analysis. Animals received (p.o.) vehicle or ZnCl 2 (10 mg/kg). After 60 min, animals were decapitated for biochemical analysis.
Tissue preparation
After decapitation, the brain of each animal was removed and the hippocampus and the prefrontal cortex were quickly dissected (4°C), placed in liquid nitrogen and stored at −80°C until use. The samples were prepared as described previously (Oliveira et al., 2008) . Briefly, tissues were mechanically homogenized in TRIS 50 mM pH 7.0, EDTA 1 mM, NaF 100 mM, PMSF 0.1 mM, Na 3 VO 4 2 mM, Triton X-100 1%, glycerol 10%, and Amresco Protease Inhibitor Cocktail catalog number M222 (Working concentration: AEBSF 0.50 mM, Aprotinin 0.30 μM, Bestatin 10.00 μM, E-64 10.00 μM, Leupeptin 10.00 μM, EDTA 50.00 μM). Lysates were centrifuged (10.000 ×g for 10 min, at 4°C) to eliminate cellular debris. The supernatants were diluted 1/1 (v/v) in TRIS 100 mM pH 6.8, EDTA 4 mM, SDS 8% and boiled for 5 min. Thereafter, samples were diluted (40% glicerol, 100 mM TRIS, bromophenol blue, pH 6.8) in the ratio 25:100 (v/v) and β-mercaptoethanol (final concentration 8%) was added on the samples. Protein content was calculated using a standard curve with bovine serum albumin as standard (Peterson, 1977) .
Western blotting
The same amount of protein (60 μg per lane) for each sample was electrophoresed in SDS-PAGE minigels (10% acrylamide) and transferred to nitrocellulose membranes using a semi-dry blotting apparatus (1.2 mA/cm 2 ; 1.5 h). To verify transfer efficiency process, membranes were stained with Ponceau Stain. After this process, the resulting membranes were incubated in a blocking solution (5% non-fat dry milk in TRIS-buffered saline (TBS)) for 60 min at room temperature, and were subsequently probed via incubation with anti-phospho-CREB (Ser133) anti-CREB (Cell Signaling, 1:1000) and anti-BDNF (Santa Cruz, 1:1000). All of the probes were diluted in a TBS solution that contained 0.1% Tween 20 (TBS-T). Next, the membranes were incubated with an anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (Millipore 1:5.000) for 60 min, and the immunoreactive bands were developed using a chemiluminescence kit (LumiGLOH, Cell Signaling, Beverly, MA, USA). All blocking and incubation steps were followed by three washes (5 min) of the membranes with TBS-T. To ascertain whether the protein load for each of the experimental groups was the same, the expression level of a housekeeping protein, β-actin, was evaluated using a mouse anti-β-actin primary antibody (Santa Cruz, 1:2000) and an anti-mouse HRP-conjugated (Millipore 1:4000) secondary antibody.
The optical density (O.D.) of the bands was quantified using Scion ImageTM (Frederick, MD, USA). The phosphorylation levels of CREB were determined as a ratio of the O.D. of the phosphorylated band over the O.D. of the total band. The BDNF immunocontent was determined from the relationship between the O.D. of the BDNF band and the O.D. of the β-actin band. Data were expressed as percentage of the control (considered as 100%).
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate the normality assumption of behavioral and biochemical data. All variables in the present study showed a normal distribution. Differences among experimental groups were determined by two-way ANOVA followed by Newman-Keuls post hoc test (behavioral analysis) or Student's t-test (immunoblotting analysis) when appropriate. A value of p b 0.05 was considered to be statistically significant. All data are presented as mean + standard error of the mean (S.E.M).
Results
Behavioral observations
To evaluate the influence of treatment of mice with inhibitors of signaling pathways in the antidepressant-like behavior elicited by ZnCl 2 , the immobility time of mice in the TST was measured (Figs. 1A, C, E, 2A, C, 3A, C). In order to rule out the possibility that the alterations in the immobility time in the TST were due to interference of the locomotor activity, the number of crossings was measured (Fig. 1B, D Fig. 4 shows a representative Western blot of the CREB phosphorylation in the hippocampus and prefrontal cortex (panels A and B, respectively) and BDNF immunocontent in the hippocampus and prefrontal cortex (panels C and D, respectively) of mice treated with ZnCl 2 (10 mg/kg). Densitometric analysis revealed that CREB phosphorylation was not affected in the hippocampus and prefrontal cortex (panels A and B, respectively) (hippocampus [t (12) 
CREB phosphorylation and BDNF immunocontent
Discussion
In the present study we showed that the administration of the inhibitors of several kinases, namely, PKA inhibitor H-89, CAMKII inhibitor KN-62, MEK1/2 inhibitors PD98059 and U0126, PKC inhibitor chelerythrine, and PI3K inhibitor LY294002 abolished the antidepressant-like effect of ZnCl 2 in TST. In addition, co-administration of sub-effective doses of ZnCl 2 and GSK-3β inhibitor AR-A014418 elicited a synergistic effect in the TST. However, CREB phosphorylation and BDNF immunocontent were not altered in the hippocampus and prefrontal cortex 60 min after the administration of ZnCl 2 to mice.
A great deal of effort has been spent in the search of adjuvant therapies that may help to treat depression. One of the nutrients that have received special attention in this regard is zinc. It has many important functions to the organism, since more than 300 enzymes have been identified as being dependent of this metal ion (McCall et al., 2000) and approximately 2000 transcription factors require zinc for the expression of their genes (Prasad, 2012) . It is noteworthy that zinc may interfere with intracellular signaling cascades. Some proteins that can be modulated by zinc are: CAMKII (Lengyel et al., 2000) , PKC (Beyersmann and Haase, 2001 ), GSK-3 (Ilouz et al., 2002; Lee et al., 2009) , Akt (Lee et al., 2009; Liang et al., 2012) , ERK (Franco et al., 2008; Park et al., 2002) , PI3K (Liang et al., 2012) , and BDNF (Franco et al., 2008; Mlyniec et al., 2013) . However, most of these actions were studied in peripheral tissues, whereas the zinc effects in the signaling pathways in the brain remain to be established.
Zinc is widely distributed in the central nervous system, being abundant in the neocortex, striatum, hippocampus, and amygdala ). In the brain, zinc in its ionic form (Zn 2 + ) is highly enriched at many glutamatergic nerve terminals and is crucial for neuronal activity (Sensi et al., 2009) . The role of zinc in depression has been extensively studied and there are several reviews about this subject (Lai et al., 2012; Nowak et al., 2005; Szewczyk et al., 2010; Szewczyk et al., 2008) . In addition to the fact that serum zinc levels are significantly lower in depressed people, there is a gradual increase in its serum concentration after antidepressant treatment (Siwek et al., 2010) . Likewise, low dietary zinc intake is associated with a greater incidence of depression in both men and women in two Australian cohorts (Vashum et al., 2014) . On the other hand, the supplementation with zinc reduces depression scores and facilitates the treatment outcome in antidepressant treatment resistant patients (Siwek et al., 2009) . Along with this conceptual framework, preclinical studies corroborate the notion that zinc exhibits antidepressant property by showing that this metal ion produces antidepressant-like effects in several animal models of depression (Cunha et al., 2008; Nowak et al., 2003; Sowa-Kucma et al., 2008) and elicits a synergistic effect with antidepressants (Cunha et al., 2008) . The mechanisms implicated in the antidepressant-like effect of zinc involve interaction with the serotonergic system (Szewczyk et al., 2009) and inhibition of NMDA receptors (Rosa et al., 2003) . It was also established that zinc may interact with GPR39 , a vertebrate G protein-coupled receptor that when activated, may stimulate PKA, PKC, CAMK and MAPK (Popovics and Stewart, 2011) . Thus, activation of the GPR39 receptor culminates in the activation of CREB (Holst et al., 2004) with the consequent BDNF increase (Alboni et al., 2011) . It was shown that mice receiving a zinc deficient diet for 6 weeks had significant reduction in GPR39 (by 53%) and BDNF (by 49%) protein expression in the frontal cortex . However, the overall understanding of the intracellular mechanisms underlying the antidepressant effect of zinc requires further studies.
Antidepressant responses have been attributed to the need of activation or inhibition of intracellular signal transduction cascades (Niciu et al., 2013) . Therefore, this study sought to investigate if inhibition of signaling pathways upstream to BDNF and related to neuroplasticity, neurogenesis and cell survival could influence the antidepressant-like effect of zinc in the TST.
Stimulation of several G-coupled receptors can activate adenylyl cyclase, which in turn converts ATP into cAMP. The enhanced PKA activity as a consequence of this event has been reported to be implicated in the antidepressant responses of several agents (Almeida et al., 2006; Liu et al., 2012; Niciu et al., 2013) , and in hippocampal neurogenesis induced by antidepressants (Anacker et al., 2011) . In line with this notion, a reduced PKA activity was found in the fibroblasts of melancholic depressive patients (Shelton et al., 1999) . Of note, our results show that the antidepressant-like effect of ZnCl 2 in the TST is dependent on the cellular signaling modulated by PKA, since the antiimmobility effect of this metal ion was not observed in mice treated with H-89. PKA activation was also shown to be implicated in some peripheral actions of zinc (Haase and Rink, 2009; von Bulow et al., 2007) .
The role of CAMKII in regulating various forms of neuroplasticity and in the pathophysiology and treatment of mood disorders has been reported (Du et al., 2004) . Long-term treatment with selective serotonin reuptake inhibitors was shown to increase autophosphorylation and activity of CAMKII (Tiraboschi et al., 2004) . In agreement, CAMKII inhibitor prevented the behavioral effects of several antidepressant compounds in mice (Almeida et al., 2006; Cunha et al., 2014) . Our data demonstrated that the antidepressant-like effect of ZnCl 2 was prevented by treatment with KN-62, suggesting that its effect in the TST is dependent on CaMKII pathway activation. This result is somewhat in agreement with a study which shows that zinc can activate CaMK-II at relatively low concentration in vitro (Lengyel et al., 2000) , and is the first to show that this pathway is involved in the behavioral response of Zn in the TST.
All PKC isozymes are highly expressed in the central nervous system, mainly in brain regions involved in mood regulation (Abrial et al., 2011) . Some studies showed that prefrontal cortex post-mortem tissue samples from suicide victims with a history of a diagnosis of depression had a decreased activity of PKC (Pandey et al., 2004) . In agreement with these data, PKC activation has been associated with antidepressant-like behaviors (Zeni et al., 2012) . In our study the antidepressant-like effect of zinc was abolished by the administration of PKC inhibitor chelerythrine, suggesting that the activation of PKC-mediated signaling pathway is involved in zinc antidepressant-like effects, somewhat in line with the fact that zinc may activate PKC in peripheral tissues (Csermely et al., 1988; Haase and Rink, 2009) .
Mitogen-activated protein kinases (MAPK) are important signal transducing enzymes that are involved in many cellular processes, including regulation of gene expression in response to extracellular stimuli, cell proliferation, cell survival and death, besides its ability to modulate the response to chemical and physical stresses (Chang and Karin, 2001) . Literature shows that inhibition of MAPK-ERK kinase (MEK; the kinase upstream to ERK1/2) induces a depressive-like effect and prevents the action of some antidepressants in mice (Duman et al., 2007; Reus et al., 2014) . Furthermore, corticosterone-induced depressive-like behaviors in mice are associated with a reduction on ERK1/2 phosphorylation (Gourley et al., 2008) . In postmortem tissue of humans with depression an increased expression of MAPK phosphatase-1 (MKP-1), a negative regulator of MAPK was shown (Duric et al., 2010) . Our results provide evidence that the activation of MEK/ERK pathway is implicated in the acute antidepressant-like effect of ZnCl 2 , considering that the anti-immobility of ZnCl 2 in the TST was abolished either by PD98059 or U0126. A modulation of this signaling pathway by zinc was also reported by other studies: a) zinc sulfate increased ERK1/2 in neuroblastoma cells ; b) chronic treatment with ZnCl 2 produced an increase in ERK phosphorylation in the cerebral cortex of rats (Franco et al., 2008) ; c) ERK phosphorylation increased with zinc supplementation and decreased when synaptic zinc was eliminated (Besser et al., 2009; Sindreu et al., 2011) ; d) zinc has been shown to transactivate TrkB receptors causing Akt and ERK1/2 activation (Huang and McNamara, 2010) .
The activation of PI3K, which catalyzes the production of phosphatidylinositol-3,4,5-trisphosphate, induces Akt activation (Cantley, 2002) . The PI3K/Akt pathway has been shown to modulate several signaling pathways, including GSK-3β. Regarding this enzyme, it is well established that Akt leads to its phosphorylation (Ser9 residue), with its consequent inactivation (Beaulieu et al., 2009) . Abnormalities in PI3K/Akt/GSK-3β pathway are implicated in depressive disorders. It has been demonstrated that the prefrontal cortex and hippocampus of suicide subjects with depression have a decreased activation of PI3K (Dwivedi et al., 2008) . Furthermore, inhibition of GSK-3β has been reported to be associated with antidepressant effects (Beaulieu et al., 2008; Rosa et al., 2008) and GSK-3β inhibitors were reported to enhance the antidepressant-like effect of some antidepressant compounds (Budni et al., 2011; Moretti et al., 2014) . Two sets of results obtained herein reinforce the notion that this pathway plays an essential role in mood modulation: a) the reversal of the anti-immobility effect of zinc by the PI3K inhibitor LY294002, and b) the anti-immobility effect observed in the TST when subeffective doses of ZnCl 2 and AR-A014418 were combined. These data indicate that the antidepressant-like effect of ZnCl 2 involves the activation of PI3K/Akt and inhibition of GSK-3β. Indeed, our results are in line with other studies which show that some of the peripheral actions of zinc may be mediated via PI3K/Akt activation (Lee et al., 2009; Liang et al., 2012) , and GSK-3β inactivation (Chanoit et al., 2008; Ilouz et al., 2002; Lee et al., 2009) .
The activation of PKA, PKC, CaMKII or MAPK can lead to phosphorylation and subsequent activation of CREB (Hashimoto et al., 2004) . Furthermore, activation of the PI3K/Akt inhibits GSK-3β, preventing the inhibitory effect of GSK-3β on CREB, thereby contributing to CREB activation. Altogether, the results presented herein firstly indicate that the antidepressant-like action of zinc in the TST is dependent on PKA, PKC, CAMKII, ERK, PI3K/Akt/GSK-3β, which are signaling pathways that converge to CREB activation and subsequent BDNF increase. This notion is in agreement with literature results which show that zinc deficiency leads to a decrease on BDNF levels in the frontal cortex and that treatment with zinc hydroaspartate for 16 days prevented the chronic unpredictable stress-induced reduction in BDNF mRNA levels in the hippocampus of rats (Cieslik et al., 2011) .
It is worth mentioning that in spite of the fact that the behavioral studies indicate that signaling pathways upstream to BDNF are involved in the antidepressant-like effect of zinc in the TST, this study did not find any alteration in CREB phosphorylation and in the BDNF immunocontent in the hippocampus and prefrontal cortex of mice treated acutely with ZnCl 2 . In line with our results, an acute administration of conventional antidepressants is reported to cause no alteration on hippocampal and/ or cerebrocortical BDNF levels (Balu et al., 2008) . Conversely, chronic treatment with zinc, similar to conventional antidepressants, (Balu et al., 2008; De Foubert et al., 2004 ) was reported to increase BDNF mRNA and protein levels in the hippocampus (Cieslik et al., 2011; Sowa-Kucma et al., 2008) or cerebral cortex (Nowak et al., 2004) of rats. Interestingly, clinical studies also report that while zinc monotherapy (30 mg for 12 weeks) increased serum BDNF levels and decreased depressive symptoms in overweight or obese subjects (Solati et al., 2014) , zinc supplementation (25 mg for 12 weeks) combined with selective serotonin reuptake inhibitor antidepressants reduced depressive symptoms, but did not change plasma levels of BDNF (Ranjbar et al., 2014) .
On the other hand, the acute administration of ketamine, an NMDA receptor antagonist that exerts rapid antidepressant effects, caused an increase (60 min) in BDNF levels in the hippocampus and prefrontal cortex of rats (Garcia et al., 2008; Zhou et al., 2014) . In spite of the ability of Zn to act as an NMDA receptor antagonist, its acute administration was not able to cause CREB activation and to enhance BDNF content in these brain structures, as opposed to ketamine. However, we could not rule out that biochemical alterations in these parameters may occur in another time point or in hippocampal or prefrontal cortex sub-regions or even in different cell types of the central nervous system. It is important to mention that Western blotting is not able to discriminate cell types and sub-regions that may be particularly involved in the antidepressant effect. Therefore, future studies using additional approaches such as immunohistochemistry may allow addressing this issue.
Conclusions
The present study significantly extends literature data regarding the mechanisms underlying the antidepressant-like action of zinc by investigating the role of cellular signaling pathways implicated with neuroplasticity, neurogenesis and cell survival in its effect in the TST. Our data clearly indicate that its anti-immobility effect in the TST may be dependent on the activation of PKA, CAMKII, ERK, PKC and PI3K/Akt pathways, and inhibition of GSK-3β signaling pathways.
